Search Results

• • 16 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies

  Authors:Ni Zhu, Haowen Xiao, Li-Mengmeng Wang, Shan Fu, Chan Zhao, and He HuangFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 201511,064 words Report 2100LAuthor(s): Ni Zhu aff1 , Haowen Xiao aff1 aff2 , Li-Mengmeng Wang aff1 , Shan Fu aff1 , Chan Zhao aff3 , He Huang [*] aff1 KEYWORDS genetic alterations; hematologic malignancies; protein tyrosine kinases; protein...

• Systems oncology: toward the clinical application of cancer systems biology

  Authors:Manuel Valladares-Ayerbes, Mar Haz-Conde, and Moises Blanco-CalvoFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20152,112 words Editorial 1820LAuthor(s): Manuel Valladares-Ayerbes aff1 , Mar Haz-Conde aff1 , Moisés Blanco-Calvo [*] aff1 KEYWORDS cancer systems biology; high-throughput technologies; precision oncology; systems biology How many times do...

• Obesity, lymphadenectomy and survival outcomes in intermediate to high-risk, early-stage endometrial cancer patients

  Authors:Faina Linkov, Robert P Edwards, Andrew Althouse, Jose A Rauh-Hain, Marcela G Del Carmen, Kyle E Freese, et al.From:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20154,840 words Report 1960LAuthor(s): Faina Linkov aff1 aff2 , Robert P Edwards aff2 , Andrew Althouse aff2 , Jose A Rauh-Hain aff3 , Marcela G Del Carmen aff3 , Kyle E Freese aff1 , Joseph L Kelley aff2 , Alexander B Olawaiye [*] aff2...

• The role of oncolytic virus immunotherapies to subvert cancer immune evasion

  Authors:Samuel T Workenhe, Meghan L Verschoor, and Karen L MossmanFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 201510,044 words Report 2030LAuthor(s): Samuel T Workenhe aff1 , Meghan L Verschoor aff1 , Karen L Mossman [*] aff1 KEYWORDS cancer immunotherapy; oncolytic virus Oncolytic viruses for cancer immunotherapy Depending on the type of...

• Erratum

  From:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 2015131 words Brief article, Corre... 1880LFollowing publication of the Case Report by Lorenzo Borgognoni, Leonardo Pescitelli, Carmelo Urso, Paola Brandani, Serena Sestini, Cristina Chiarugi, Riccardo Gelli, Vanni Giannotti & Gianni Gerlini, titled 'A rare case...

• Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP

  Authors:Yoshimitsu Kobayashi, Yoshito Komatsu, Satoshi Yuki, Hiraku Fukushima, Takahide Sasaki, Ichiro Iwanaga, et al.From:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20156,439 words Report 1520LAuthor(s): Yoshimitsu Kobayashi aff1 , Yoshito Komatsu [*] aff2 , Satoshi Yuki aff1 , Hiraku Fukushima aff2 , Takahide Sasaki aff1 , Ichiro Iwanaga aff3 , Minoru Uebayashi aff3 , Hiroyuki Okuda aff4 , Takaya Kusumi aff5...

• Circulating tumor DNA: new horizons for improving cancer treatment

  Authors:Georgios D Lianos, Alberto Mangano, William C Cho, Gianlorenzo Dionigi, and Dimitrios H RoukosFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20152,393 words Editorial, Report 1750LAuthor(s): Georgios D Lianos aff1 aff2 , Alberto Mangano aff3 , William C Cho aff4 , Gianlorenzo Dionigi aff3 , Dimitrios H Roukos [*] aff1 aff2 aff5 KEYWORDS cancer; circulating tumor DNA; clonal evolution;...

• Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?

  Authors:William Jacot, Charles Theillet, Severine Guiu, and Pierre-Jean LamyFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20152,318 words Report 1850LAuthor(s): William Jacot [*] aff1 aff2 aff3 , Charles Theillet aff3 , Séverine Guiu aff1 , Pierre-Jean Lamy aff4 KEYWORDS 53BP1; BRCA1 ; breast cancer; methylation; ovarian cancer; targeted therapies Genetic...

• Chemotherapy is getting 'smarter'

  Author:Thomas MehrlingFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20152,061 words Editorial 1830LAuthor(s): Thomas Mehrling [*] KEYWORDS antibody-drug conjugate; chemotherapy; fusion molecule; histone-deacetylase inhibitor Chemotherapy is becoming 'smarter' specifically targeting and killing tumor cells...

• Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus

  Authors:Ketty Peris, Lisa Licitra, Paolo A Ascierto, Renzo Corvo, Marco Simonacci, Franco Picciotto, et al.From:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20156,481 words Report 1740LAuthor(s): Ketty Peris [*] aff1 , Lisa Licitra aff2 , Paolo A Ascierto aff3 , Renzo Corvò aff4 , Marco Simonacci aff5 , Franco Picciotto aff6 , Giulio Gualdi aff7 , Giovanni Pellacani aff8 , Armando Santoro aff9...

• Gastrointestinal metastases from prostate cancer: a review of the literature

  Authors:Francesca Maines, Orazio Caffo, Antonello Veccia, and Enzo GalligioniFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20158,513 words Report 2260LAuthor(s): Francesca Maines aff1 , Orazio Caffo [*] aff1 , Antonello Veccia aff1 , Enzo Galligioni aff1 KEYWORDS atypical metastases; castration-resistant; gastrointestinal metastases; prostate cancer Prostate...

• Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer

  Authors:Luisa Foltran, Giovanna De Maglio, Nicoletta Pella, Paola Ermacora, Giuseppe Aprile, Elena Masiero, et al.From:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20155,904 words Report 1530LAuthor(s): Luisa Foltran [*] aff1 aff2 , Giovanna De Maglio aff3 , Nicoletta Pella aff1 , Paola Ermacora aff1 , Giuseppe Aprile aff1 , Elena Masiero aff3 , Mariella Giovannoni aff1 , Emiliana Iaiza aff1 , Giovanni...

• Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment

  Authors:Alberto Mangano, Georgios D Lianos, Alessandro Mangano, Luigi Boni, and Gianlorenzo DionigiFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20152,814 words Report 2140LAuthor(s): Alberto Mangano [*] aff1 , Georgios D Lianos aff2 , Alessandro Mangano aff3 , Luigi Boni aff1 , Gianlorenzo Dionigi aff1 KEYWORDS cancer drug resistance; intertumor heterogeneity; intratumor...

• Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting

  Authors:Vito Lorusso, Meinolf Karthaus, and Matti AaproFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20159,724 words Report 1940LAuthor(s): Vito Lorusso [*] aff1 , Meinolf Karthaus aff2 , Matti Aapro aff3 KEYWORDS antiemetic; chemotherapy-induced nausea and vomiting; NEPA; netupitant; palonosetron Chemotherapy-induced nausea and vomiting...

• Vemurafenib for the treatment of BRAF mutant metastatic melanoma

  Authors:Juan Martin-Liberal and James LarkinFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 20157,902 words Report 1690LAuthor(s): Juan Martin-Liberal aff1 , James Larkin [*] aff1 KEYWORDS BRAF ; chemistry; dabrafenib; ipilimumab; MAPK; MEK; melanoma; pharmacodynamics; pharmacokinetics; vemurafenib The management of malignant...

• Shifting paradigms in the treatment of chronic lymphocytic leukemia

  Authors:Philip A Thompson, Elizabeth J Shpall, and Michael J KeatingFrom:Future Oncology (Vol. 11, Issue 4) Peer-Reviewed

  Feb. 201513,659 words Report 1800LAuthor(s): Philip A Thompson aff1 , Elizabeth J Shpall aff2 , Michael J Keating [*] aff1 KEYWORDS biology; CLL; future treatment; genetics Chronic lymphocytic leukemia (CLL) is a clonal disorder of mature...